ER+ breast cancers with HER2-amplification tend to have early recurrence if treated with hormonal therapy alone, likely because the activation of the HER2 pathway leads to independence from ER- mediated signalling (see reviews above, also [15], [16]). Here, ESR1 is linked to breast cancer.